Medical research firm Spotlight Innovation Inc. has chosen Orlando-based Maitland Labs to initiate product development and production at the latter’s sterile fill drug production plant, now under construction and expected to open in September.
Spotlight Innovation develops proprietary cancer drugs and infectious disease solutions utilizing partnerships with universities and other research facilities. It intends to utilize the new Florida site for both pre-clinical testing and clinical trials.
"As we continue to move forward with our pre-clinical and clinical trials, the opportunity to be based in a state-of-the-art, first-in-class processing facility will offer us consistency and greater efficiency in the production and delivery of clinical samples, and future manufacturing capability," Paul Reid, who serves as Spotlight Innovation's director of product development, said.
The plant will be FDA registered and compliant with Good Manufacturing Practice standards.
Spotlight Innovation identifies and acquires rights to pioneering platform technology contenders, providing value-added development capability and financial support in order to drive development progress, cash flow, future profitability and tangible value.
Headquartered in West Des Moines, Iowa, Spotlight Innovation maintains a unique benchmark model, planning ahead for long-term commercial partnerships and licensing options. Its mission is to meaningfully impact patient health by advancing new platform biotechnologies for cancer and infectious disease.
6750 Westown Pkwy
West Des Moines, IA 50266